Skip to main content

Lumbar Intervertebral Disc Degeneration

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
Autologous Adipose Tissue derived MSCs TransplantationN/A
R-Bio
R-BioTX - Houston
1 program
Autologous Adipose Tissue derived MSCs TransplantationN/A1 trial
Active Trials
NCT01643681Withdrawn0Est. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
R-BioAutologous Adipose Tissue derived MSCs Transplantation

Clinical Trials (1)

NCT01643681R-BioAutologous Adipose Tissue derived MSCs Transplantation

Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration

Start: Jul 2012Est. completion: Dec 20150
N/AWithdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.